Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk

J Infect Dis. 2002 Oct 15;186(8):1173-6. doi: 10.1086/343805. Epub 2002 Sep 20.

Abstract

Secretory leukocyte protease inhibitor (SLPI), a protein found in saliva, breast milk, and genital secretions, is capable of inhibiting human immunodeficiency virus (HIV) type 1 in vitro. The aim of this study was to determine whether SLPI in infant saliva provides protection against mother-to-child HIV-1 transmission. In total, 602 saliva specimens were collected from 188 infants at birth and at ages 1, 3, and 6 months. Infants' median salivary SLPI concentrations were higher at birth than at 6 months (341 vs. 219 ng/mL; P=.001). There was no association between SLPI concentration and HIV-1 transmission overall. However, among 122 breast-fed infants who were HIV-1 uninfected at 1 month, higher salivary SLPI levels were associated with a decreased risk of HIV-1 transmission through breast milk (hazard ratio, 0.5; 95% confidence interval, 0.3-0.9; P=.03). These results suggest that SLPI plays an important role in reducing HIV-1 transmission through breast milk.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / analysis
  • Anti-HIV Agents / metabolism
  • Disease Susceptibility*
  • Female
  • HIV Infections / transmission*
  • HIV-1 / physiology*
  • Humans
  • Infant
  • Infant, Newborn
  • Infectious Disease Transmission, Vertical*
  • Milk, Human / virology*
  • Pregnancy
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins / analysis
  • Proteins / metabolism*
  • Risk Factors
  • Saliva / chemistry*
  • Secretory Leukocyte Peptidase Inhibitor

Substances

  • Anti-HIV Agents
  • Proteinase Inhibitory Proteins, Secretory
  • Proteins
  • SLPI protein, human
  • Secretory Leukocyte Peptidase Inhibitor